Bristol-Myers Squibb Company (BMY) reported $50.03B of revenue for the twelve months ended Sep 30, 2026. That is up 4.2% from the year before. Revenue for fiscal 2025 was $48.19B.

Yes. Bristol-Myers Squibb Company earned $9.24B in net income for the twelve months ended Sep 30, 2026, a net margin of 18.5%.

How much cash and debt does BMY have?

Bristol-Myers Squibb Company reported $9.57B in cash and cash equivalents and $42.88B of debt on its most recent balance sheet in SEC filings.

How fast is BMY revenue growing?

Bristol-Myers Squibb Company's revenue changed -0.2% in fiscal 2025, to $48.19B. Its compound annual growth rate was +2.5% over 5 years and +11.3% over 10 years.

What is BMY gross margin?

Bristol-Myers Squibb Company's gross profit was $34.64B on $50.03B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 69.2%.

What is BMY free cash flow?

Bristol-Myers Squibb Company generated $9.29B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $10.65B less capital expenditures.

What is BMY earnings per share?

Diluted earnings per share were $4.52 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did BMY last report financial results?

The latest statements here come from Bristol-Myers Squibb Company's 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.

Financials · BMY

Bristol-Myers Squibb Company (BMY) financials

For the twelve months ended Sep 30, 2026, Bristol-Myers Squibb Company reported $50.03B of revenue and $9.24B of net income.

Revenue, TTM: $50.03B
Revenue growth, YoY: +4.2%
Net income, TTM: $9.24B
Net income growth, YoY: +53.1%
Net margin: 18.5%
Free cash flow, TTM: $9.29B
EPS, diluted, TTM: $4.52
Cash: $9.57B
Total debt: $42.88B
P/E: 13.74
P/S: 2.54
Market cap: $127.01B

Annual revenue$48.19B

FY2016FY2025

Annual net income$7.05B

FY2016FY2025

Annual free cash flow$12.85B

FY2016FY2025

BMY revenue and earnings growth

BMY revenueQ3 2026$13.07B

Quarter YoY: +6.9%
QoQ: +0.7%
FY YoY: -0.2%
5Y CAGR: +2.5%
10Y CAGR: +11.3%

BMY revenue was $13.07B in fiscal Q3 2026 (ended Sep 30, 2026), up 6.9% from a year earlier and up 0.7% from the prior quarter. For the full fiscal 2025 it was $48.19B, down 0.2% from fiscal 2024. Compound annual growth was +2.5% over 5 years and +11.3% over 10 years. It rose in 7 of the last 10 fiscal years.

BMY net incomeQ3 2026$2.16B

Quarter YoY: -1.8%
QoQ: -34.8%
10Y CAGR: +16.2%

BMY net income was $2.16B in fiscal Q3 2026 (ended Sep 30, 2026), down 1.8% from a year earlier and down 34.8% from the prior quarter. For the full fiscal 2025 it was $7.05B, compared with -$8.95B in fiscal 2024. Compound annual growth was +16.2% over 10 years.

BMY EPSQ3 2026$1.05

Quarter YoY: -2.8%
QoQ: -35.2%
10Y CAGR: +14.0%

BMY diluted EPS was $1.05 in fiscal Q3 2026 (ended Sep 30, 2026), down 2.8% from a year earlier and down 35.2% from the prior quarter. For the full fiscal 2025 it was $3.46, compared with -$4.41 in fiscal 2024. Compound annual growth was +14.0% over 10 years.

BMY free cash flowQ3 2026$3.84B

Quarter YoY: -36.0%
QoQ: +24.3%
FY YoY: -7.9%
5Y CAGR: -0.7%
10Y CAGR: +25.9%

BMY free cash flow was $3.84B in fiscal Q3 2026 (ended Sep 30, 2026), down 36.0% from a year earlier and up 24.3% from the prior quarter. For the full fiscal 2025 it was $12.85B, down 7.9% from fiscal 2024. Compound annual growth was -0.7% over 5 years and +25.9% over 10 years. It rose in 8 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$48.19B	$48.30B	$45.01B	$46.16B	$46.38B	$42.52B	$26.14B	$22.56B	$20.78B	$19.43B
Cost of revenue	$13.94B	$13.97B	$10.69B	$10.14B	$9.94B	$11.77B	$8.08B	$6.47B	$6.01B	$4.97B
Gross profit	$34.26B	$34.33B	$34.31B	$36.02B	$36.45B	$30.75B	$18.07B	$16.09B	$14.68B	$14.48B
Research and development	$9.95B	$11.16B	$9.30B	$9.51B	$10.20B	$10.05B	$6.15B	$6.33B	$6.47B	$5.01B
Selling, general and admin	$7.27B	$8.41B	$7.77B	$7.81B	$7.69B	$7.66B	$4.87B	$4.55B	$4.75B	$4.98B
Interest expense	$1.89B	$1.95B	$1.17B	$1.23B	$1.33B	$1.42B	$656.00M	$183.00M	$196.00M	$167.00M
Pre-tax income	$9.33B	-$8.38B	$8.44B	$7.71B	$8.10B	-$6.87B	$4.97B	$5.97B	$5.13B	$5.92B
Income tax	$2.27B	$554.00M	$400.00M	$1.37B	$1.08B	$2.12B	$1.51B	$1.02B	$4.16B	$1.41B
Net income	$7.05B	-$8.95B	$8.03B	$6.33B	$6.99B	-$9.02B	$3.44B	$4.92B	$1.01B	$4.46B
EPS, basic	$3.47	-$4.41	$3.88	$2.97	$3.15	-$3.99	$2.02	$3.01	$0.61	$2.67
EPS, diluted	$3.46	-$4.41	$3.86	$2.95	$3.12	-$3.99	$2.01	$3.01	$0.61	$2.65
Diluted shares	2.04B	2.03B	2.08B	2.15B	2.25B	2.26B	1.71B	1.64B	1.65B	1.68B

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$10.21B	$10.35B	$11.52B	$9.32B	$14.32B	$14.97B	$12.82B	$6.91B	$5.42B	$4.24B
Short-term investments	-	-	-	$130.00M	$2.99B	$1.28B	$3.05B	$1.85B	$1.39B	$2.11B
Receivables	$9.59B	$9.01B	$8.88B	$8.15B	$7.98B	$7.22B	$6.48B	$4.64B	$4.35B	$3.77B
Inventory	$2.69B	$2.56B	$2.66B	$2.34B	$2.10B	$2.07B	$4.29B	$1.20B	$1.17B	$1.24B
Current assets	$29.39B	$29.78B	$31.77B	$27.27B	$33.26B	$30.19B	$29.35B	$17.72B	$14.85B	$13.70B
Goodwill	$21.75B	$21.72B	$21.17B	$21.15B	$20.50B	$20.55B	$22.49B	$6.54B	$6.86B	$6.88B
Total assets	$90.04B	$92.60B	$95.16B	$96.82B	$109.31B	$118.48B	$129.94B	$34.99B	$33.55B	$33.71B
Current liabilities	$23.42B	$23.77B	$22.26B	$21.89B	$21.87B	$19.08B	$18.30B	$10.65B	$9.56B	$8.84B
Short-term debt	$2.26B	$2.05B	$3.12B	$4.26B	$4.95B	$2.34B	$3.35B	$1.70B	$987.00M	$992.00M
Long-term debt	$42.85B	$47.60B	$36.65B	$35.06B	$39.60B	$48.34B	$43.39B	$5.65B	$6.97B	$5.72B
Total debt	$45.11B	$49.65B	$39.77B	$39.32B	$44.55B	$50.68B	$46.73B	$7.35B	$7.96B	$6.71B
Total liabilities	$71.53B	$76.22B	$65.67B	$65.70B	$73.31B	$80.60B	$78.25B	$20.86B	$21.70B	$17.36B
Shareholders' equity	$18.47B	$16.34B	$29.43B	$31.06B	$35.95B	$37.82B	$51.60B	$14.03B	$11.74B	$16.18B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$14.16B	$15.19B	$13.86B	$13.07B	$16.21B	$14.05B	$8.21B	$7.07B	$5.28B	$3.06B
Capital expenditures	$1.31B	$1.25B	$1.21B	$1.12B	$973.00M	$753.00M	$836.00M	$951.00M	$1.05B	$1.22B
Free cash flow	$12.85B	$13.94B	$12.65B	$11.95B	$15.23B	$13.30B	$7.37B	$6.12B	$4.22B	$1.84B
Investing cash flow	-$4.13B	-$21.35B	-$2.29B	-$1.06B	-$538.00M	-$10.86B	-$9.91B	-$2.00B	-$66.00M	$1.48B
Financing cash flow	-$10.35B	$5.13B	-$9.42B	-$16.96B	-$16.22B	-$1.15B	$7.62B	-$3.54B	-$4.08B	-$2.65B
Dividends paid	$5.04B	$4.86B	$4.74B	$4.63B	$4.40B	$4.08B	$2.68B	$2.61B	$2.58B	$2.55B
Share repurchases	$0	$0	$5.16B	$8.00B	$6.29B	$1.55B	$7.30B	$320.00M	$2.47B	$231.00M
Stock-based compensation	$553.00M	$507.00M	$518.00M	$457.00M	$583.00M	$779.00M	$441.00M	$221.00M	$199.00M	$205.00M
Depreciation and amortization	$4.01B	$9.60B	$9.76B	$10.28B	$10.69B	$10.38B	$1.75B	$637.00M	$789.00M	$382.00M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	-0.2%	7.3%	-2.5%	-0.5%	9.1%	62.6%	15.9%	8.6%	6.9%	17.3%
Net income growth, YoY	-	-	26.8%	-9.5%	-	-	-30.1%	388.6%	-77.4%	184.8%
EPS growth, YoY	-	-	30.8%	-5.4%	-	-	-33.2%	393.4%	-77.0%	184.9%
Gross margin	71.1%	71.1%	76.2%	78.0%	78.6%	72.3%	69.1%	71.3%	70.7%	74.5%
Net margin	14.6%	-18.5%	17.8%	13.7%	15.1%	-21.2%	13.2%	21.8%	4.8%	22.9%
Free cash flow margin	26.7%	28.9%	28.1%	25.9%	32.8%	31.3%	28.2%	27.1%	20.3%	9.5%
Return on equity	38.2%	-54.8%	27.3%	20.4%	19.5%	-23.8%	6.7%	35.1%	8.6%	27.6%
Return on assets	7.8%	-9.7%	8.4%	6.5%	6.4%	-7.6%	2.6%	14.1%	3.0%	13.2%
Current ratio	1.26	1.25	1.43	1.25	1.52	1.58	1.60	1.66	1.55	1.55
Debt to equity	2.44	3.04	1.35	1.27	1.24	1.34	0.91	0.52	0.68	0.41

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$13.07B	$12.97B	$11.49B	$12.50B	$12.22B	$12.27B	$11.20B	$12.34B	$11.89B	$12.20B	$11.87B	$11.48B
Cost of revenue	$4.15B	$3.73B	$3.42B	$4.10B	$3.44B	$3.37B	$3.03B	$4.81B	$2.96B	$3.27B	$2.93B	$2.75B
Gross profit	$8.92B	$9.25B	$8.07B	$8.40B	$8.79B	$8.90B	$8.17B	$7.53B	$8.94B	$8.93B	$8.93B	$8.73B
Research and development	$2.37B	$2.96B	$2.65B	$2.59B	$2.53B	$2.58B	$2.26B	$3.19B	$2.37B	$2.90B	$2.69B	$2.48B
Selling, general and admin	$1.70B	$1.83B	$1.62B	$2.18B	$1.79B	$1.71B	$1.58B	$2.14B	$1.98B	$1.93B	$2.37B	$2.07B
Interest expense	$403.00M	$407.00M	$411.00M	$432.00M	$480.00M	$485.00M	$494.00M	$496.00M	$505.00M	$521.00M	$425.00M	$316.00M
Pre-tax income	$2.54B	$4.09B	$3.24B	$1.47B	$3.11B	$1.77B	$2.97B	$175.00M	$1.68B	$1.29B	-$11.52B	$1.67B
Income tax	$374.00M	$770.00M	$561.00M	$384.00M	$919.00M	$460.00M	$509.00M	$99.00M	$461.00M	-$398.00M	$392.00M	-$88.00M
Net income	$2.16B	$3.32B	$2.68B	$1.09B	$2.20B	$1.31B	$2.46B	$72.00M	$1.21B	$1.68B	-$11.91B	$1.76B
EPS, basic	$1.06	$1.62	$1.31	$0.54	$1.08	$0.64	$1.21	$0.05	$0.60	$0.83	-$5.89	$0.87
EPS, diluted	$1.05	$1.62	$1.31	$0.54	$1.08	$0.64	$1.20	$0.05	$0.60	$0.83	-$5.89	$0.87
Diluted shares	2.05B	2.05B	2.05B	-	2.04B	2.04B	2.04B	-	2.03B	2.03B	2.02B	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$9.57B	$8.72B	$9.57B	$10.21B	$15.73B	$12.61B	$10.88B	$10.35B	$7.89B	$6.30B	$9.33B	$11.52B
Receivables	$9.19B	$9.08B	$7.95B	$9.59B	$9.62B	$9.71B	$9.06B	$9.01B	$9.32B	$9.75B	$8.83B	$8.88B
Inventory	$2.70B	$2.74B	$2.76B	$2.69B	$2.76B	$2.74B	$2.67B	$2.56B	$3.33B	$3.08B	$2.98B	$2.66B
Current assets	$29.77B	$28.58B	$27.21B	$29.39B	$35.63B	$33.22B	$30.78B	$29.78B	$28.07B	$26.89B	$28.67B	$31.77B
Goodwill	$21.73B	$21.74B	$21.74B	$21.75B	$21.75B	$21.78B	$21.74B	$21.72B	$21.75B	$21.73B	$21.74B	$21.17B
Total assets	$88.77B	$87.63B	$86.48B	$90.04B	$96.89B	$94.68B	$92.43B	$92.60B	$93.67B	$94.65B	$99.03B	$95.16B
Current liabilities	$18.75B	$18.66B	$19.16B	$23.42B	$28.14B	$27.53B	$24.07B	$23.77B	$22.64B	$23.27B	$25.82B	$22.26B
Short-term debt	$1.03B	$1.03B	$2.31B	$2.26B	$4.51B	$4.71B	$3.55B	$2.05B	$1.08B	$3.53B	$6.19B	$3.12B
Long-term debt	$41.85B	$42.09B	$42.15B	$42.85B	$44.47B	$44.47B	$46.16B	$47.60B	$48.67B	$48.86B	$49.49B	$36.65B
Total debt	$42.88B	$43.12B	$44.46B	$45.11B	$48.98B	$49.19B	$49.71B	$49.65B	$49.75B	$52.39B	$55.68B	$39.77B
Total liabilities	$65.37B	$65.31B	$66.37B	$71.53B	$78.29B	$77.19B	$74.98B	$76.22B	$76.47B	$77.58B	$82.48B	$65.67B
Shareholders' equity	$23.40B	$22.32B	$20.07B	$18.47B	$18.55B	$17.43B	$17.39B	$16.34B	$17.14B	$17.02B	$16.49B	$29.43B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$4.18B	$3.39B	$1.10B	$1.97B	$6.31B	$3.92B	$1.95B	$4.44B	$5.59B	$2.33B	$2.83B	$4.25B
Capital expenditures	$344.00M	$305.00M	$347.00M	$370.00M	$320.00M	$361.00M	$260.00M	$378.00M	$324.00M	$262.00M	$284.00M	$330.00M
Free cash flow	$3.84B	$3.09B	$757.00M	$1.60B	$5.99B	$3.56B	$1.69B	$4.06B	$5.27B	$2.06B	$2.55B	$3.92B
Investing cash flow	-$2.10B	-$1.61B	-$131.00M	-$1.46B	-$1.70B	-$473.00M	-$499.00M	-$196.00M	-$219.00M	-$1.32B	-$19.62B	-$1.35B
Financing cash flow	-$1.22B	-$2.63B	-$1.56B	-$6.03B	-$1.49B	-$1.84B	-$993.00M	-$1.64B	-$3.85B	-$4.02B	$14.64B	$967.00M
Dividends paid	$1.29B	$1.29B	$1.28B	$1.26B	$1.26B	$1.26B	$1.26B	$1.22B	$1.22B	$1.22B	$1.21B	$1.16B
Share repurchases	-	-	-	-	-	-	-	$0	$0	$0	$0	$0
Stock-based compensation	$138.00M	$135.00M	$146.00M	$133.00M	$139.00M	$137.00M	$144.00M	$120.00M	$129.00M	$125.00M	$133.00M	$127.00M
Depreciation and amortization	$626.00M	$594.00M	$594.00M	$977.00M	$1.01B	$1.01B	$1.01B	$1.88B	$2.59B	$2.60B	$2.53B	$2.46B

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	6.9%	5.7%	2.6%	1.3%	2.8%	0.6%	-5.6%	7.5%	8.4%	8.7%	4.7%	0.6%
Net income growth, YoY	-1.8%	153.2%	9.0%	1409.7%	81.8%	-22.0%	-	-95.9%	-37.2%	-19.0%	-	-12.9%
EPS growth, YoY	-2.8%	153.1%	9.2%	980.0%	80.0%	-22.9%	-	-94.3%	-35.5%	-16.2%	-	-8.4%
Gross margin	68.3%	71.3%	70.2%	67.2%	71.9%	72.5%	72.9%	61.0%	75.1%	73.2%	75.3%	76.1%
Net margin	16.5%	25.6%	23.3%	8.7%	18.0%	10.7%	21.9%	0.6%	10.2%	13.8%	-100.4%	15.4%
Free cash flow margin	29.4%	23.8%	6.6%	12.8%	49.0%	29.0%	15.1%	32.9%	44.3%	16.9%	21.5%	34.2%
Current ratio	1.59	1.53	1.42	1.26	1.27	1.21	1.28	1.25	1.24	1.16	1.11	1.43
Debt to equity	1.83	1.93	2.22	2.44	2.64	2.82	2.86	3.04	2.90	3.08	3.38	1.35

Source: XBRL data Bristol-Myers Squibb Company files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BMY peers

Company	Revenue	Growth	Net income	Net margin	Market cap
BMY	$50.03B	+4.2%	$9.24B	18.5%	$127.01B
JNJJohnson & Johnson	$99.33B	+7.8%	$16.09B	16.2%	$664.95B
ABBVAbbVie Inc.	$66.01B	+10.7%	$10.34B	15.7%	$514.92B
MRKMerck & Company Inc.	$67.38B	+4.9%	$2.45B	3.6%	$361.71B
NVSNovartis AG	$54.53B	+8.4%	$13.98B	25.6%	$310.17B
AZNAstraZeneca PLC	$58.74B	+8.6%	$10.22B	17.4%	$289.10B
AMGNAmgen Inc.	$38.90B	+8.2%	$9.39B	24.1%	$249.05B
GILDGilead Sciences Inc.	$30.99B	+6.5%	-$3.86B	-12.5%	$207.00B
PFEPfizer Inc.	$63.63B	+1.3%	$4.03B	6.3%	$167.49B

BMY FAQ

9 questions

What is BMY revenue?
Bristol-Myers Squibb Company (BMY) reported $50.03B of revenue for the twelve months ended Sep 30, 2026. That is up 4.2% from the year before. Revenue for fiscal 2025 was $48.19B.
Is BMY profitable?
Yes. Bristol-Myers Squibb Company earned $9.24B in net income for the twelve months ended Sep 30, 2026, a net margin of 18.5%.
How much cash and debt does BMY have?
Bristol-Myers Squibb Company reported $9.57B in cash and cash equivalents and $42.88B of debt on its most recent balance sheet in SEC filings.
How fast is BMY revenue growing?
Bristol-Myers Squibb Company's revenue changed -0.2% in fiscal 2025, to $48.19B. Its compound annual growth rate was +2.5% over 5 years and +11.3% over 10 years.
What is BMY gross margin?
Bristol-Myers Squibb Company's gross profit was $34.64B on $50.03B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 69.2%.
What is BMY free cash flow?
Bristol-Myers Squibb Company generated $9.29B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $10.65B less capital expenditures.
What is BMY earnings per share?
Diluted earnings per share were $4.52 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did BMY last report financial results?
The latest statements here come from Bristol-Myers Squibb Company's 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.
Where does this BMY financial data come from?
Quantisnow builds these statements from the structured XBRL data Bristol-Myers Squibb Company files with the SEC. It is provided for information only and is not investment advice.